VRDN – viridian therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

VRDN

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/8

08:35 am

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

4/8

08:35 am

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

4/7

02:11 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

4/7

02:11 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

4/7

02:11 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

4/7

09:02 am

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

4/7

09:02 am

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

4/2

08:36 am

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

3/31

12:38 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

3/31

12:38 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

3/31

12:38 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

3/31

10:06 am

vrdn

Rating for VRDN

Medium Report

Rating for VRDN

Report

3/31

10:06 am

vrdn

Rating for VRDN

Medium Report

Rating for VRDN

Report

3/31

09:46 am

vrdn

Rating for VRDN

Medium Report

Rating for VRDN

Report

3/31

09:46 am

vrdn

Rating for VRDN

Medium Report

Rating for VRDN

Report

3/30

01:45 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

3/30

01:45 pm

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

3/11

09:03 am

vrdn

Viridian Therapeutics (VRDN) had its "outperform" rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.

Low Report

Viridian Therapeutics (VRDN) had its "outperform" rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.

Report

3/11

09:03 am

vrdn

Viridian Therapeutics (VRDN) had its "outperform" rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.

Low Report

Viridian Therapeutics (VRDN) had its "outperform" rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.

Report

3/11

08:50 am

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

3/11

08:50 am

vrdn

Rating for VRDN

Low Report

Rating for VRDN

Report

2/27

01:12 pm

vrdn

Rating for VRDN

Medium Report

Rating for VRDN

Report

2/27

01:12 pm

vrdn

Rating for VRDN

Medium Report

Rating for VRDN

Report

2/4

08:03 am

vrdn

Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.

Medium Report

Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.

Report

2/4

06:20 am

vrdn

Rating for VRDN

Medium Report

Rating for VRDN

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.